Table 1.
Variable | Value |
---|---|
Demographics: | |
Age (years), mean ± SD | 56 ± 12.9 |
Male gender, n (%) | 129 (57.9) |
PsA duration (years), mean ± SD | 16.9 ± 12.4 |
Psoriasis skin disease duration (years), mean ± SD | 28.1 ± 14.5 |
BMI, mean ± SD | 29.8 ± 6.1 |
Smoking | |
Current, n (%) | 29 (13) |
Past, n (%) | 70 (31.4) |
Clinical activity measures: | |
Tender joints count, mean ± SD | 2.5 ± 5.3 |
Swollen joint count, mean ± SD | 1.1 ± 3.3 |
Clinical enthesitis, n (%) | 31 (13.9) |
Dactylitis, n (%) | 9 (4) |
PASI, mean ± SD | 2.6 ± 5.8 |
Nail lesions, n (%) | 59 (26.4) |
HLA-B*27 | 34 (15.5) |
Radiographic evaluation: | |
modified Steinbrocker score | |
mean ± SD | 18.7 ± 33.6 |
median (25th, 75th percentile) | 4 (0, 20) |
Arthritis mutilans, n (%) | 20 (9) |
Joint ankylosis, n (%) | 26 (11.7) |
Periostitis, n (%) | 49 (22.2) |
mSASSS, | |
mean ± SD | 1.7 ± 7.2 |
median (25th, 75th percentile) | 0 (0, 0) |
Sacroiliitis, n (%), | 82 (37.1) |
Sonographic evaluation: | |
MASEI, mean ± SD | 15.7 ± 12.6 |
Treatment: | |
DMARDs – current use, n (%) | 102 (45.7) |
DMARDs – ever use, n (%) | 181 (81.2) |
Biologics – current use, n (%) | 119 (53.4) |
Biologics – ever use, n (%) | 130 (58.3) |
PsA psoriatic arthritis, BMI body mass index, BODPASI psoriasis area and severity index, HLA-B*27 human leukocyte antigen B*27, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, MASEI MAdrid Sonography Enthesitis Index, DMARDs disease-modifying antirheumatic drugs